A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo
Open Access
- 25 June 2007
- journal article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 7 (1) , 3
- https://doi.org/10.1186/1472-6823-7-3
Abstract
Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of hepatic glucose output and tissue glucose disposal. In such animals, bromocriptine also reduces hepatic triglyceride synthesis and free fatty acid mobilization, manifesting decreases in both plasma triglycerides and free fatty acids. In clinical trials, morning administration of Cycloset™ either as monotherapy or adjunctive therapy to sulfonylurea or insulin reduces HbA1c levels relative to placebo by 0.55–1.2. Cycloset™ therapy also reduces plasma triglycerides and free fatty acid by approximately 25% and 20%, respectively, among those also receiving sulfonylurea therapies. The effects of once-daily morning Cycloset™ therapy on glycemic control and plasma lipids are demonstrable throughout the diurnal portion of the day (7 a.m. to 7 p.m.) across postprandial time points.Keywords
This publication has 14 references indexed in Scilit:
- Standards of Medical Care in DiabetesDiabetes Care, 2004
- Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob MiceNeuroendocrinology, 2000
- ASSOCIATION OF THE ANTIDIABETIC EFFECTS OF BROMOCRIPTINE WITH A SHIFT IN THE DAILY RHYTHM OF MONOAMINE METABOLISM WITHIN THE SUPRACHIASMATIC NUCLEI OF THE SYRIAN HAMSTERChronobiology International, 2000
- Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetesExpert Opinion on Investigational Drugs, 1999
- Intracerebroventricular Administration of Bromocriptine Ameliorates the Insulin-Resistant/Glucose-Intolerant State in HamstersNeuroendocrinology, 1999
- Bromocriptine Reduces Obesity, Glucose Intolerance and Extracellular Monoamine Metabolite Levels in the Ventromedial Hypothalamus of Syrian HamstersNeuroendocrinology, 1998
- Circadian Neuroendocrine Role in Age-Related Changes in Body Fat Stores and Insulin Sensitivity of the Male Sprague-Dawley RatChronobiology International, 1993
- Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratusMetabolism, 1991
- Bromocriptine Alters Hormone Rhythms and Lipid Metabolism in SwineAnnals of Nutrition and Metabolism, 1989
- Fat, Energy and Mammalian SurvivalAmerican Zoologist, 1976